{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T02:45:36Z","timestamp":1769741136042,"version":"3.49.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,10,1]],"date-time":"2019-10-01T00:00:00Z","timestamp":1569888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Heart Journal"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1016\/j.ahj.2019.06.008","type":"journal-article","created":{"date-parts":[[2019,6,20]],"date-time":"2019-06-20T03:43:33Z","timestamp":1561002213000},"page":"42-52","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Amyloid cardiomyopathy in a large integrated health care system"],"prefix":"10.1016","volume":"216","author":[{"given":"Peter","family":"Czobor","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yun-Yi","family":"Hung","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Baer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dana","family":"McGlothlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dana","family":"Weisshaar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Zaroff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ahj.2019.06.008_bb0005","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1056\/NEJM199709253371306","article-title":"The systemic amyloidoses","volume":"337","author":"Falk","year":"1997","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ahj.2019.06.008_bb0010","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1161\/CIRCULATIONAHA.108.843334","article-title":"Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types","volume":"120","author":"Rapezzi","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2019.06.008_bb0015","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1080\/07853890701842988","article-title":"Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study","volume":"40","author":"Tanskanen","year":"2008","journal-title":"Ann Med"},{"key":"10.1016\/j.ahj.2019.06.008_bb0020","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1093\/eurheartj\/ehv338","article-title":"Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction","volume":"36","author":"Gonzalez-Lopez","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2019.06.008_bb0025","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1182\/blood.V79.7.1817.1817","article-title":"Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989","volume":"79","author":"Kyle","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.ahj.2019.06.008_bb0030","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1186\/1471-2458-12-974","article-title":"Incidence and survival in non-hereditary amyloidosis in Sweden","volume":"12","author":"Hemminki","year":"2012","journal-title":"BMC Public Health"},{"key":"10.1016\/j.ahj.2019.06.008_bb0035","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/bjh.12286","article-title":"Systemic amyloidosis in England: an epidemiological study","volume":"161","author":"Pinney","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ahj.2019.06.008_bb0040","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/1471-2350-14-88","article-title":"Incidence of hereditary amyloidosis and autoinflammatory diseases in Sweden: endemic and imported diseases","volume":"14","author":"Hemminki","year":"2013","journal-title":"BMC Med Genet"},{"key":"10.1016\/j.ahj.2019.06.008_bb0045","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.jacc.2016.03.596","article-title":"Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (Transthyretin Amyloid Outcome Survey)","volume":"68","author":"Maurer","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2019.06.008_bb0050","doi-asserted-by":"crossref","first-page":"703","DOI":"10.2105\/AJPH.82.5.703","article-title":"Overcoming the absence of socioeconomic data in medical records: validation and application of a census-based methodology","volume":"82","author":"Krieger","year":"1992","journal-title":"Am J Public Health"},{"key":"10.1016\/j.ahj.2019.06.008_bb0055","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1001\/archinte.165.18.2105","article-title":"Sex and racial\/ethnic disparities in outcomes after acute myocardial infarction: a cohort study among members of a large integrated health care delivery system in northern California","volume":"165","author":"Iribarren","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.ahj.2019.06.008_bb0060","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1038\/leu.2014.218","article-title":"A\u00a0matched comparison of cyclophosphamide, bortezomib and dexamethasone (CVD) versus risk-adapted cyclophosphamide, thalidomide and dexamethasone (CTD) in AL amyloidosis","volume":"28","author":"Venner","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.ahj.2019.06.008_bb0065","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1182\/blood-2015-01-620302","article-title":"A\u00a0European collaborative study of cyclophosphamide, bortezomib, and dexamethasone in upfront treatment of systemic AL amyloidosis","volume":"126","author":"Palladini","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.ahj.2019.06.008_bb0070","doi-asserted-by":"crossref","first-page":"2941","DOI":"10.1016\/j.jacc.2016.03.593","article-title":"Efficacy of Chemotherapy for Light-Chain Amyloidosis in Patients Presenting With Symptomatic Heart Failure","volume":"67","author":"Sperry","year":"2016","journal-title":"J\u00a0Am Coll Cardiol"},{"key":"10.1016\/j.ahj.2019.06.008_bb0075","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1182\/bloodadvances.2018016402","article-title":"Epidemiology of AL amyloidosis: a real-world study using US claims data","volume":"2","author":"Quock","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.ahj.2019.06.008_bb0080","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.1161\/01.CIR.0000068314.02595.B2","article-title":"Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis","volume":"107","author":"Palladini","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2019.06.008_bb0085","doi-asserted-by":"crossref","first-page":"3751","DOI":"10.1200\/JCO.2004.03.029","article-title":"Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis","volume":"22","author":"Dispenzieri","year":"2004","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ahj.2019.06.008_bb0090","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1016\/S0140-6736(03)13396-X","article-title":"Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins","volume":"361","author":"Dispenzieri","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.ahj.2019.06.008_bb0095","doi-asserted-by":"crossref","first-page":"297","DOI":"10.4065\/83.3.297","article-title":"Serum uric acid: novel prognostic factor in primary systemic amyloidosis","volume":"83","author":"Kumar","year":"2008","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.ahj.2019.06.008_bb0100","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1093\/ehjci\/jew325","article-title":"Prognostic utility of the Perugini grading of 99mTc-DPD scintigraphy in transthyretin (ATTR) amyloidosis and its relationship with skeletal muscle and soft tissue amyloid","volume":"18","author":"Hutt","year":"2017","journal-title":"Eur Heart J Cardiovasc Imaging"},{"key":"10.1016\/j.ahj.2019.06.008_bb0105","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1093\/eurheartj\/ehx589","article-title":"A\u00a0new staging system for cardiac transthyretin amyloidosis","volume":"39","author":"Gillmore","year":"2018","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ahj.2019.06.008_bb0110","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.117.004000","article-title":"Use of Serum Transthyretin as a Prognostic Indicator and Predictor of Outcome in Cardiac Amyloid Disease Associated With Wild-Type Transthyretin","volume":"11","author":"Hanson","year":"2018","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.ahj.2019.06.008_bb0115","article-title":"Subtype-Specific Interactions and Prognosis in Cardiac Amyloidosis","volume":"5","author":"Sperry","year":"2016","journal-title":"J\u00a0Am Heart Assoc"},{"key":"10.1016\/j.ahj.2019.06.008_bb0120","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1002\/ajh.23141","article-title":"Best use of cardiac biomarkers in patients with AL amyloidosis and renal failure","volume":"87","author":"Palladini","year":"2012","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ahj.2019.06.008_bb0125","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.amjcard.2005.05.057","article-title":"Is elevated plasma B-natriuretic peptide in amyloidosis simply a function of the presence of heart failure?","volume":"96","author":"Nordlinger","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2019.06.008_bb0130","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1161\/01.CIR.0000039105.49749.6F","article-title":"Lifetime risk for developing congestive heart failure: the Framingham Heart Study","volume":"106","author":"Lloyd-Jones","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2019.06.008_bb0135","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/j.amjcard.2009.06.051","article-title":"Is age really a non-modifiable cardiovascular risk factor?","volume":"104","author":"Kannel","year":"2009","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2019.06.008_bb0140","doi-asserted-by":"crossref","first-page":"e146","DOI":"10.1161\/CIR.0000000000000485","article-title":"Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association","volume":"135","author":"Benjamin","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2019.06.008_bb0145","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/gim.2016.200","article-title":"Transthyretin V122I (pV142I)\u2217 cardiac amyloidosis: an age-dependent autosomal dominant cardiomyopathy too common to be overlooked as a cause of significant heart disease in elderly African Americans","volume":"19","author":"Buxbaum","year":"2017","journal-title":"Genet Med"},{"key":"10.1016\/j.ahj.2019.06.008_bb0150","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0002-9149(82)90270-3","article-title":"Amyloid cardiomyopathy: characterization by a distinctive voltage\/mass relation","volume":"49","author":"Carroll","year":"1982","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.ahj.2019.06.008_bb0155","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1161\/01.RES.0000126569.75419.74","article-title":"Human amyloidogenic light chains directly impair cardiomyocyte function through an increase in cellular oxidant stress","volume":"94","author":"Brenner","year":"2004","journal-title":"Circ Res"},{"key":"10.1016\/j.ahj.2019.06.008_bb0160","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1161\/CIRCULATIONAHA.115.018852","article-title":"Heart Failure Resulting From Age-Related Cardiac Amyloid Disease Associated With Wild-Type Transthyretin: A Prospective, Observational Cohort Study","volume":"133","author":"Connors","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.ahj.2019.06.008_bb0165","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2217\/ahe.13.10","article-title":"Comparison of cardiac amyloidosis due to wild-type and V122I transthyretin in older adults referred to an academic medical center","volume":"9","author":"Givens","year":"2013","journal-title":"Aging health"}],"container-title":["American Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000287031930153X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S000287031930153X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T06:02:38Z","timestamp":1757570558000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S000287031930153X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10]]},"references-count":33,"alternative-id":["S000287031930153X"],"URL":"https:\/\/doi.org\/10.1016\/j.ahj.2019.06.008","relation":{},"ISSN":["0002-8703"],"issn-type":[{"value":"0002-8703","type":"print"}],"subject":[],"published":{"date-parts":[[2019,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Amyloid cardiomyopathy in a large integrated health care system","name":"articletitle","label":"Article Title"},{"value":"American Heart Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ahj.2019.06.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}